Literature DB >> 18793857

Structure-activity study at positions 3 and 4 of human neuropeptide S.

Valeria Camarda1, Claudio Trapella, Girolamo Calo', Remo Guerrini, Anna Rizzi, Chiara Ruzza, Stella Fiorini, Erika Marzola, Rainer K Reinscheid, Domenico Regoli, Severo Salvadori.   

Abstract

Neuropeptide S (NPS) has been identified as the endogenous ligand of a previously orphan receptor now named NPSR. Previous studies demonstrated that the N-terminal sequence Phe(2)-Arg(3)-Asn(4) of the peptide is crucial for biological activity. Here, we report on a focused structure-activity study of Arg(3) and Asn(4) that have been replaced with a series of coded and non-coded amino acids. Thirty-eight human NPS analogues were synthesized and pharmacologically tested for intracellular calcium mobilization using HEK293 cells stably expressing the mouse NPSR. The results of this study demonstrated the following NPS position 3 structure-activity features: (i) the guanidine moiety and its basic character are not crucial requirements, (ii) an aliphatic amino acid with a linear three carbon atom long side chain is sufficient to bind and fully activate NPSR, (iii) the receptor pocket allocating the position 3 side chain can accommodate slightly larger side chains at least to a certain degree [hArg, Arg(NO2) or Arg(Me)2 but not Arg(Tos)]. Position 4 seems to be more sensitive to amino acids replacement compared to position 3; in fact, all the amino acid replacements investigated produced either an important decrease of biological activity or generated inactive derivatives suggesting a pivotal role of the Asn(4) side chain for NPS bioactivity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18793857     DOI: 10.1016/j.bmc.2008.08.073

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  5 in total

1.  Identification of the first biased NPS receptor agonist that retains anxiolytic and memory promoting effects with reduced levels of locomotor stimulation.

Authors:  Stewart D Clark; Terrence P Kenakin; Steven Gertz; Carla Hassler; Elaine A Gay; Tiffany L Langston; Rainer K Reinscheid; Scott P Runyon
Journal:  Neuropharmacology       Date:  2017-03-03       Impact factor: 5.250

2.  Further studies at neuropeptide s position 5: discovery of novel neuropeptide S receptor antagonists.

Authors:  Remo Guerrini; Valeria Camarda; Claudio Trapella; Girolamo Caló; Anna Rizzi; Chiara Ruzza; Stella Fiorini; Erika Marzola; Rainer K Reinscheid; Domenico Regoli; Severo Salvadori
Journal:  J Med Chem       Date:  2009-07-09       Impact factor: 7.446

3.  Synthesis and biological activity of human neuropeptide S analogues modified in position 5: identification of potent and pure neuropeptide S receptor antagonists.

Authors:  Remo Guerrini; Valeria Camarda; Claudio Trapella; Girolamo Calò; Anna Rizzi; Chiara Ruzza; Stella Fiorini; Erika Marzola; Rainer K Reinscheid; Domenico Regoli; Severo Salvadori
Journal:  J Med Chem       Date:  2009-01-22       Impact factor: 7.446

Review 4.  Pharmacology, Physiology and Genetics of the Neuropeptide S System.

Authors:  Rainer K Reinscheid; Chiara Ruzza
Journal:  Pharmaceuticals (Basel)       Date:  2021-04-23

5.  In vitro and in vivo pharmacological characterization of a neuropeptide S tetrabranched derivative.

Authors:  Chiara Ruzza; Anna Rizzi; Davide Malfacini; Alice Pulga; Salvatore Pacifico; Severo Salvadori; Claudio Trapella; Rainer K Reinscheid; Girolamo Calo; Remo Guerrini
Journal:  Pharmacol Res Perspect       Date:  2015-01-05
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.